Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface
Authors:
- Hassina MassudiHMHassina Massudi
- Jie-Si LuoJie-Si Luo
- Jessica K. HolienJessica K. Holien
- Satyanarayana GaddeSGSatyanarayana Gadde
- Sukriti KrishanSKSukriti Krishan
- Mika HerathMHMika Herath
- Jessica KoachJKJessica Koach
- Brendan W. StevensonBSBrendan W. Stevenson
- Michael A. GormanMGMichael A. Gorman
- Pooja VenkatPVPooja Venkat
- Chelsea MayohCMChelsea Mayoh
- Xue-Qun LuoXLXue-Qun Luo
Open Access
Abstract
MYCN is a major oncogenic driver for neuroblastoma tumorigenesis, yet there are no direct MYCN inhibitors. We have previously identified PA2G4 as a direct protein-binding partner of MYCN and drive neuroblastoma tumorigenesis. A small molecule known to bind PA2G4, WS6, significantly decreased tumorigenicity in TH-MYCN neuroblastoma mice, along with the inhibition of PA2G4 and MYCN interactions. Here, we identified a number of novel WS6 analogues, with 80% structural similarity, and used surface plasmon resonance assays to determine their binding affinity. Analogues #5333 and #5338 showed direct binding towards human recombinant PA2G4. Importantly, #5333 and #5338 demonstrated a 70-fold lower toxicity for normal human myofibroblasts compared to WS6. Structure-activity relationship analysis showed that a 2,3 dimethylphenol was the most suitable substituent at the R1 position. Replacing the trifluoromethyl group on the phenyl ring at the R2 position, with a bromine or hydrogen atom, increased the difference between efficacy against neuroblastoma cells and normal myofibroblast toxicity. The WS6 analogues inhibited neuroblastoma cell phenotype in vitro, in part through effects on apoptosis, while their anti-cancer effects required both PA2G4 and MYCN expression. Collectively, chemical inhibition of PA2G4-MYCN binding by WS6 analogues represents a first-in-class drug discovery which may have implications for other MYCN-driven cancers.Keywords
Funding Information
- National Health and Medical Research Council (APP1016699, 10/TPG/1-13, PG-11-06, RG21-08, APP1125171, APP1117183)
- Cancer Institute NSW (APP1016699, 10/TPG/1-13, PG-11-06, RG21-08, APP1125171, APP1117183)
- Cancer Council NSW (APP1016699, 10/TPG/1-13, PG-11-06, RG21-08, APP1125171, APP1117183)
- National Health and Medical Research Council (APP1016699, 10/TPG/1-13, PG-11-06, RG21-08, APP1125171, APP1117183)
- 5-point Foundation Postdoctoral Fellowship (APP1016699, 10/TPG/1-13, PG-11-06, RG21-08, APP1125171, APP1117183)
- National Health and Medical Research Council (APP1016699, 10/TPG/1-13, PG-11-06, RG21-08, APP1125171, APP1117183)
This publication has 38 references indexed in Scilit:
- DAVID-WS: a stateful web service to facilitate gene/protein list analysisBioinformatics, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein StabilityPLOS Genetics, 2011
- Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian CancersPLOS ONE, 2011
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Myc proteins as therapeutic targetsOncogene, 2010
- Mass Spectrometry-Based Label-Free Quantitative ProteomicsJournal of Biomedicine and Biotechnology, 2009
- Cholinergic switch associated with morphological differentiation in neuroblastomaThe Journal of Pathology, 2009
- Global Identification of Myc Target Genes Reveals Its Direct Role in Mitochondrial Biogenesis and Its E-Box Usage In VivoPLOS ONE, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007